Ethylene

Ethylene

SCHEMBL3645192

C=C.CCOC(C)OCC.O=Cc1cccc(Br)c1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.41
SLC6A19 Q695T7 1/20 0.40
HSD17B3 P37058 1/20 0.37
HTT P42858 2/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD11B1 P28845 1/20 0.36
LMNA P02545 1/20 0.35
PKM P14618 1/20 0.35
CHRNA7 P36544 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A3 P47895 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6712899 0.97 ALDH1A1 (0.62) ALDH1A1MAOAMAOBSMN1; SMN2SLC6A19
Ethylene SCHEMBL233909 0.82 TP53 (0.39) ALDH1A1MAOAMAOBMAPTNPSR1
Ethylene SCHEMBL8532842 0.81 LMNA (0.41) ALDH1A1MAOAMAOBSMN1; SMN2MAPT
Benzaldehyde SCHEMBL11346796 0.81 ALDH1A1 (0.50) ALDH1A1MAOAMAOBLMNAMEN1
Ethylene SCHEMBL10571152 0.80 ALDH1A1 (0.91) ALDH1A1MAOAMAOBSMN1; SMN2SLC6A19
Ethylene SCHEMBL3648042 0.79 MAOA (0.38) ALDH1A1MAOAMAOBSMN1; SMN2LMNA
Ethylene SCHEMBL6226363 0.79 LMNA (0.48) ALDH1A1SMN1; SMN2MAPTLMNAALDH1A3
SCHEMBL10638856 0.79 TP53 (0.41) ALDH1A1MAOAMAOBMAPTNPSR1
Ethylene SCHEMBL8169366 0.79 MAOA (0.44) ALDH1A1MAOAMAOBSMN1; SMN2CYP1A2
SCHEMBL569625 0.78 LMNA (0.43) ALDH1A1MAOAMAOBSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101835771-A Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors NOVARTIS AG 2010-09-15 CN disclosed
EP-2190833-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS Novartis Ag (CH) 2010-06-02 EP disclosed
WO-2009024615-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2009-02-26 WO disclosed
US-20090054427-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS BRIARD EMMANUELLE 2009-02-26 US disclosed
US-4789754-A PRODUCTION OF CHRYSANTHEMIC ESTERS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1988-12-06 US disclosed
US-4594355-A Phenyl ring with a 2,2-dimethylcyclopropanecarboxylic group on ring and a dihalovinyl group in position 3 NATIONAL RESEARCH DEVELOPMENT CORP. (GB) 1986-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054427-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS BACE2, BACE1, APP ALDH1A1 2720/4885MAOA 618/4885MAOB 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.